Contineum Therapeutics plans to spend most of its IPO cash on clinical testing of a lead drug candidate in development for idiopathic pulmonary fibrosis and multiple sclerosis. This small molecule blocks a competitive target pursued by several other companies, including Bristol Myers Squibb and AbbVie.
AbbVie is acquiring Landos Biopharma, whose lead drug is a small molecule that takes a novel approach to treating ulcerative colitis. Preliminary proof-of-concept data from a Phase 2 study are expected later this year.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Mirador Therapeutics applies machine learning to human data to discover new immunology and inflammation drugs. The startup’s management includes several from the executive team of Prometheus Biosciences, an immunology biotech bought by Merck last year.
Contineum Therapeutics, which emerged from a Verant Ventures startup creation engine, has filed paperwork for an IPO. The biotech’s clinical-stage pipeline spans multiple sclerosis, idiopathic pulmonary fibrosis, and depression.
Placing research in the hands of a large pharmaceutical company is a goal of many biotech companies. IFM Therapeutics has now done it three times and its latest deal is the second time Novartis is the acquirer.
Cour Pharmaceuticals’ nanoparticles reprogram the immune system to stop inflammation behind autoimmune disease. Three big pharma companies joined the startup’s Series A financing, which will fund clinical trials in type 1 diabetes and myasthenia gravis.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Allakos’s lirentelimab did not beat a placebo in separate Phase 2 tests in atopic dermatitis and spontaneous chronic urticaria. A restructuring now turns the biotech’s focus to an early-stage drug candidate also designed to treat inflammation.
Evelo Biosciences’ vision of using microbes to engage the gut and modulate immune responses remains unrealized. With financing prospects dim and no one willing to take on its assets, Evelo is dissolving its business.
Celldex drug barzolvolimab has mid-stage results in a chronic inflammatory skin disease that top those of an approved Genentech drug and two experimental Novartis therapies. The biotech is preparing to advance its drug to Phase 3 testing in 2024.
Available atopic dermatitis drugs work by blocking inflammation, but Triveni Bio is developing an antibody that addresses a root cause of the chronic condition. The startup is out of stealth to advance its lead program and a pipeline of other inflammation and immunology drugs.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Abivax pulled off stock market deals in the U.S. and Europe that infuse the biotech with capital to continue clinical development of a small molecule for inflammation that’s differentiated from biologic therapies. In other biotech IPO news, Cargo Therapeutics and Invea Therapeutics both filed paperwork to go public.
Roche’s Telavant acquisition comes as the Roivant Sciences subsidiary prepares its main asset for Phase 3 testing in ulcerative colitis. The antibody drug candidate blocks a novel target for inflammation and fibrosis that’s also the focus of clinical-stage programs of other big pharma companies.
Pfizer’s new FDA-approved ulcerative colitis drug Velsipity comes from its $6.7 billion Arena Pharmaceuticals acquisition. The small molecule will compete against blockbuster Bristol Myers Squibb drug Zeposia, which addresses the same target.
Gilead Sciences is partnering with Tentarix Biotherapeutics, a startup developing multifunctional antibody drugs that it calls "Tentacles." Tentarix’s technology offers the potential to selectively address targets in cancer and inflammation.
Sanofi is interested in Recludix Pharma’s approach to treating inflammation with an oral small molecule that targets a protein thought to be undruggable. If it works, the drug could have safety and dosing advantages over currently available biologic drugs, including blockbuster Sanofi drug Dupixent.